Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials